Shanghai Ark Biopharmaceutical Co., Ltd.
PrivateLast Round
Series D
Jul 14, 2022
Est. Valuation
$694.8M
Total Funding Raised
$146.3M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Shanghai Ark Biopharmaceutical Co., Ltd. is a biopharmaceutical company that discovers and develops therapeutics for unmet medical needs in respiratory and pediatric diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Hardware Sales, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai Ark Biopharmaceutical Co., Ltd. Comparables
Compare Shanghai Ark Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enanta Pharmaceuticals | 77% | |
| Pfizer | 77% | |
| Sanofi | 71% |
Shanghai Ark Biopharmaceutical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 14, 2022 | ||||
| Series C | Jan 22, 2021 | ||||
| Series A Extension | Feb 6, 2017 | ||||
| Series A | Apr 9, 2015 | ||||
| Angel | Feb 1, 2014 |
Shanghai Ark Biopharmaceutical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriental Fortune Capital | Series C |
| Loyal Valley Capital | Series D |
| Oriza Holdings | Series C, Series D |
| Hillhouse Investment | Series C |
| Daoyuan Capital | Series C |
| 德同资本 | Series C |
| Jiangsu Ruihua Investment Holding Group | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 15, 2026
Monthly visitors increased 268% MoM.
- Jan 20, 2026
Monthly visitors increased 189% MoM, reaching 503.
Recent news
Latest coverage and updates
- is_developingAug 13, 2026
Ark Biosciences is developing AK0406 on Aug 13th '26.
- partners_withAug 13, 2026
Ark Biosciences partners with Scripps Research Translational Institute.
- is_developingAug 13, 2026
Ark Biosciences is developing antiviral drug-fc conjugate candidate AK0406 on Aug 13th '26.
- is_developingAug 13, 2026
Ark Biosciences is developing AK0406 for both pre-exposure and post-exposure prophylaxis..
- partners_withAug 13, 2026
Ark Biosciences partnered with Genentech, Inc. on Jul 25th '26.
Shanghai Ark Biopharmaceutical Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Shanghai Ark Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.
Is Shanghai Ark Biopharmaceutical Co., Ltd. a public or private company?
Shanghai Ark Biopharmaceutical Co., Ltd. is a private company.
What is the current stock price of Shanghai Ark Biopharmaceutical Co., Ltd.?
Shanghai Ark Biopharmaceutical Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.
How much is Shanghai Ark Biopharmaceutical Co., Ltd. worth (valuation)?
Valuation information for Shanghai Ark Biopharmaceutical Co., Ltd. is not publicly available.
Can I buy Shanghai Ark Biopharmaceutical Co., Ltd. stock?
Shanghai Ark Biopharmaceutical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Shanghai Ark Biopharmaceutical Co., Ltd.'s last funding round?
Funding round information for Shanghai Ark Biopharmaceutical Co., Ltd. is not publicly available.
Who are the main investors in Shanghai Ark Biopharmaceutical Co., Ltd.?
Investor information for Shanghai Ark Biopharmaceutical Co., Ltd. is not publicly disclosed.
Will Shanghai Ark Biopharmaceutical Co., Ltd. IPO soon?
No public IPO plans have been announced for Shanghai Ark Biopharmaceutical Co., Ltd..
How can I track Shanghai Ark Biopharmaceutical Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shanghai Ark Biopharmaceutical Co., Ltd.'s secondary market activity and sign up for updates.